演題詳細

ポスター / Poster

ポスター 6 (Poster 6) :AML:発症・治療・その他

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
安部 明弘 (Akihiro Abe):1
1:藤田保健衛生大学 血液内科
 
前へ戻る

Successful second alloSCT with RIC for relapsed blastic plasmacytoid dendritic cell neoplasm

演題番号 : PS-1-39

加藤 丈晴 (Takeharu Kato):1、波多 智子 (Tomoko Hata):1、田口 潤 (Jun Taguchi):1、田口 正剛 (Masataka Taguchi):1、蓬莱 真喜子 (Makiko Hourai):1、牧山 純也 (Junya Makiyama):1、新野 大介 (Daisuke Niino):2、對馬 秀樹 (Hideki Tsushima):1、今泉 芳孝 (Yoshitaka Imaizumi):1、今西 大介 (Daisuke Imanishi):1、大島 孝一 (Koichi Ohshima):2、宮崎 泰司 (Yasushi Miyazaki):1

1:Department of Hematology, Nagasaki University Hospital, Japan、2:Department of Pathology, Kurume University, Japan

 

[Background] Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive malignancy derived from the precursors of plasmacytoid dendritic cells with a high frequency of cutaneous and bone marrow involvement. Recently, a favorable outcome of allogeneic stem cell transplantation (alloSCT) following multi-agent chemotherapy was reported. We experienced a case of relapsed BPDCN for which 2nd alloSCT with reduced conditioning intensity (RIC) provided durable 2nd remission. [case] A 62-year-old male was admitted to Nagasaki University Hospital with subcutaneous tumor on the left arm. His marrow was filled with blasts which showed CD4+, CD33+, CD123+, and HLA-DR+. The pathological examination of the skin biopsy specimen revealed the abnormal cells were CD4+, CD56+, CD123+, and TCL-1+. The diagnosis of BPDCN was made. He received induction chemotherapy followed by RIC alloSCT from an unrelated donor during first complete remission (CR), but BPDCN relapsed 4 months after transplantation. Re-induction chemotherapy brought 2nd CR, then he received 2nd alloSCT from another unrelated donor. The conditioning for 2nd alloSCT consisted of fludarabin, busulfan, and 2Gy total body irradiation. Tacrolimus and methotrexate were used as prophylaxis for graft-versus-host disease (GVHD). He experienced transient grade II acute GVHD. He is in 2nd CR for 9 months after 2nd transplantation with full donor chimerism. [Conclusion] AlloSCT with RIC could be a promising treatment for elderly patients with BPDCN.

前へ戻る